Stock Track | GRAIL Soars 5.22% as Canaccord Genuity Maintains Buy Rating and Boosts Price Target

Stock Track11-17

GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer detection technologies, saw its stock price climb on the back of maintained confidence from Wall Street analysts.

Canaccord Genuity reaffirmed its Buy rating on GRAIL, signaling continued optimism about the company's prospects. In a notable move, the firm also raised its price target for GRAIL from $85 to $105, representing a significant 23.5% increase in their valuation of the company. This upward revision suggests that Canaccord Genuity sees substantial upside potential in GRAIL's stock.

The positive analyst action comes as GRAIL continues to make strides in the field of early cancer detection. While specific details of the analyst's reasoning were not provided, the maintained Buy rating and increased price target typically reflect confidence in a company's fundamentals, growth prospects, and market position. Investors appear to be reacting favorably to this vote of confidence, as evidenced by the pre-market stock movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164255267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164255267","market":"us","top_or_hot":-1,"title":"Stock Track | GRAIL Soars 5.22% as Canaccord Genuity Maintains Buy Rating and Boosts Price Target","media":"Stock Track","content":"<p>GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer detection technologies, saw its stock price climb on the back of maintained confidence from Wall Street analysts.</p>\n\n<p>Canaccord Genuity reaffirmed its Buy rating on GRAIL, signaling continued optimism about the company's prospects. In a notable move, the firm also raised its price target for GRAIL from $85 to $105, representing a significant 23.5% increase in their valuation of the company. This upward revision suggests that Canaccord Genuity sees substantial upside potential in GRAIL's stock.</p>\n\n<p>The positive analyst action comes as GRAIL continues to make strides in the field of early cancer detection. While specific details of the analyst's reasoning were not provided, the maintained Buy rating and increased price target typically reflect confidence in a company's fundamentals, growth prospects, and market position. Investors appear to be reacting favorably to this vote of confidence, as evidenced by the pre-market stock movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL Soars 5.22% as Canaccord Genuity Maintains Buy Rating and Boosts Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL Soars 5.22% as Canaccord Genuity Maintains Buy Rating and Boosts Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-17 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer detection technologies, saw its stock price climb on the back of maintained confidence from Wall Street analysts.</p>\n\n<p>Canaccord Genuity reaffirmed its Buy rating on GRAIL, signaling continued optimism about the company's prospects. In a notable move, the firm also raised its price target for GRAIL from $85 to $105, representing a significant 23.5% increase in their valuation of the company. This upward revision suggests that Canaccord Genuity sees substantial upside potential in GRAIL's stock.</p>\n\n<p>The positive analyst action comes as GRAIL continues to make strides in the field of early cancer detection. While specific details of the analyst's reasoning were not provided, the maintained Buy rating and increased price target typically reflect confidence in a company's fundamentals, growth prospects, and market position. Investors appear to be reacting favorably to this vote of confidence, as evidenced by the pre-market stock movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1164255267","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164255267","pubTimestamp":1763391166,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"个股追踪|Canaccord Genuity维持买入评级并上调目标价，GRAIL飙升5.22%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer detection technologies, saw its stock price climb on the back of maintained confidence from Wall Street analysts.\nCanaccord Genuity reaffirmed its Buy rating on GRAIL, signaling continued optimism about the company's prospects. In a notable move, the firm also raised its price target for GRAIL from $85 to $105, representing a significant 23.5% increase in their valuation of the company. This upward revision suggests that Canaccord Genuity sees substantial upside potential in GRAIL's stock.\nThe positive analyst action comes as GRAIL continues to make strides in the field of early cancer detection. While specific details of the analyst's reasoning were not provided, the maintained Buy rating and increased price target typically reflect confidence in a company's fundamentals, growth prospects, and market position. Investors appear to be reacting favorably to this vote of confidence, as evidenced by the pre-market stock movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164255267","isCrawlerRequest":true}